Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation

Hart, Robert G., Pearce, Lesly A., Aguilar, Maria I.·2007·Annals of Internal Medicine
DOI 10.7326/0003-4819-146-12-200706190-00007

Cited by (1,005)

Items 601–700 of 1,005

  1. Long-term survival after ischemic stroke in patients with atrial fibrillation
    Margaret C. Fang, Alan S. Go, Yuchiao Chang, Leila H. Borowsky, Niela K. Pomernacki, Natalia V. Udaltsova, Daniel E. Singer · 2014 · Neurology
  2. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort
    Menno Volkert Huisman, Chang Sheng, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Kenneth Jay Rothman, Christine Teutsch, Nils Schoof, Eva Kleine, Dorothee B. Bartels et al. · 2016 · EP Europace
  3. Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation
    Jung‐Im Shin, Alex M. Secora, G. Caleb Alexander, Lesley A. Inker, Josef Coresh, Alex R. Chang, Morgan Erika Grams · 2018 · Clinical Journal of the American Society of Nephrology
  4. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study
    Duncan Wilson, Gareth Ambler, Gargi Banerjee, Clare Shakeshaft, Hannah Cohen, Tarek Ahmed Yousry, Rustam Al‐Shahi Salman, Gregory Y.H. Lip, Henry Houlden, Martin M. Brown et al. · 2018 · Journal of Neurology Neurosurgery & Psychiatry
  5. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis
    Maurizio Paciaroni, Birsen İnce, Bo Hu, Jiann‐Shing Jeng, Kürşad Kutluk, Liping Liu, Min Lou, Vladimir Anatolyevich Parfenov, Ka Sing Wong, Babak Zamani et al. · 2019 · Cardiovascular Therapeutics
  6. Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing
    Moudallel, Souad, Steurbaut, Stephane, Cornu, Pieter, Dupont, Alain · 2018 · Frontiers in Pharmacology
  7. Wavelet Entropy Automatically Detects Episodes of Atrial Fibrillation from Single-Lead Electrocardiograms
    Juan Ródenas, Manuel García, Raúl Alcaraz, José Joaquín Rieta · 2015 · Entropy
  8. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients
    Ariel Dogliotti, Ernesto Paolasso, Robert Patrick Giugliano · 2013 · Heart
  9. Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke
    Katrin Wasser, Mark Weber-Krüger, Sonja Gröschel, Timo Uphaus, Jan Liman, Gerhard F. Hamann, Pawel Kermer, Joachim Seegers, Lutz Binder, Götz Gelbrich et al. · 2019 · Stroke
  10. The relationship between atrial fibrillation and coronary artery disease: Understanding common denominators
    Mario Mekhael, Nassir F. Marrouche, Abdel Hadi El Hajjar, Eoin Donnellan · 2022 · Trends in Cardiovascular Medicine
  11. The Prevalence, Impact and Economic Implications of Atrial Fibrillation in Stroke: What Progress Has Been Made?
    Nadine E. Andrew, Amanda Gay Thrift, Dominique Ann-Michele Cadilhac · 2013 · Neuroepidemiology
  12. An update on cardioembolic stroke
    Nicolas U. Weir · 2008 · Postgraduate Medical Journal
  13. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA 2 DS 2 -VASc Risk Factor Be Anticoagulated?
    Laurent Fauchier, Nicolas Clémenty, Arnaud Bisson, Fabrice Ivanés, Denis Angoulvant, Dominique Babuty, Gregory Y.H. Lip · 2016 · Stroke
  14. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source
    Roland C. Veltkamp, Lesly A. Pearce, Eleni Korompoki, Mukul Sharma, Scott Eric Kasner, Danilo Toni, Sebastián F. Ameriso, Hardi Mundl, Turgut Tatlisumak, Graeme J. Hankey et al. · 2020 · JAMA Neurology
  15. Antiplatelet and Anticoagulant Agents in Heart Failure
    Paul Alfred Gurbel, Udaya S. Tantry · 2014 · JACC Heart Failure
  16. Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin
    Richard Paul Whitlock, Jeff S. Healey, Stuart J. Connolly · 2009 · Circulation
  17. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS <sub>2</sub> to the CHA <sub>2</sub> DS <sub>2</sub> -VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry’s Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry
    Katz, David F., Maddox, Thomas M., Turakhia, Mintu, Gehi, Anil, O’Brien, Emily C., Lubitz, Steven A., Turchin, Alexander, Doros, Gheorghe, Lei, Lanyu, Varosy, Paul et al. · 2017 · Circulation: Cardiovascular Quality and Outcomes
  18. Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni, Monia Marchetti, Silvana Quaglini, Nicola Lucio Liberato · 2013 · Clinical Drug Investigation
  19. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care
    Richard F. Hobbs, Clare J Taylor, Geert Jan Geersing, Frans Hendrik Rutten, Judith Rixt Brouwer, on behalf of the European Primary Care Cardiovascular Society (EPCCS) SPAF working group · 2015 · European Journal of Preventive Cardiology
  20. Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort
    Mi Kyoung Son, Nam-Kyoo Lim, Hyung Woo Kim, Hyun‐Young Park · 2017 · PLoS ONE
  21. Warfarin in haemodialysis patients with atrial fibrillation: what benefit?
    Felix Yang, Denise E. Chou, Paul Schweitzer, Sam Hanon · 2010 · EP Europace
  22. Rivaroxaban vs. Warfarin in Japanese Patients With Non-Valvular Atrial Fibrillation in Relation to Age
    Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin‐ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu C. Kato et al. · 2014 · Circulation Journal
  23. Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
    Benjamin Adam Steinberg, Peter J. Shrader, Laine Elliott Thomas, Jack Ansell, Gregg C. Fonarow, Bernard John Gersh, Elaine M. Hylek, Peter Russell Kowey, Kenneth W. Mahaffey, Emily Claire O'Brien et al. · 2017 · American Heart Journal
  24. Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation
    Alexander C. Perino, Jun Fan, Susan K. Schmitt, Mariam Askari, Daniel W. Kaiser, Abhishek J. Deshmukh, Paul A. Heidenreich, Christopher Swan, Sanjiv M. Narayan, Paul J. Wang et al. · 2017 · Journal of the American College of Cardiology
  25. Atrial fibrillation detected initially during acute medical illness: A systematic review
    William F. McIntyre, Kevin John Um, Christopher C. Cheung, Emilie P. Belley‐Côté, Orvie Dingwall, Philip James Devereaux, Jorge A. Wong, David Conen, Richard Paul Whitlock, Stuart J. Connolly et al. · 2018 · European Heart Journal Acute Cardiovascular Care
  26. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis
    Derek Henry Wallace Little, Chatree Chai‐Adisaksopha, Christopher Hillis, Daniel M. Witt, Manuel Monréal, Mark Andrew Crowther, Deborah M. Siegal · 2019 · Thrombosis Research
  27. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease
    Matthew R. Weir, Veronica Ashton, Kenneth Todd Moore, Shubham Shrivastava, Eric David Peterson, Eric M. Ammann · 2020 · American Heart Journal
  28. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
    Karsten Bruins Slot, Eivind Berge · 2018 · Cochrane Database of Systematic Reviews
  29. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation
    Daniele Pastori, Pasquale Pignatelli, Mirella Saliola, Roberto Carnevale, Tommasa Vicario, Maria Del Ben, Roberto Cangemi, Francesco Barillà, Gregory Y.H. Lip, Francesco Violi · 2015 · International Journal of Cardiology
  30. Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update
    Ole De Backer, Samer Arnous, Nikolaj Ihlemann, Niels Grove Vejlstrup, Erik Ole Jørgensen, Steen Michael Pehrson, Torben Krieger, Pascal Meier, Lars Søndergaard, Olaf Walter Franzen · 2014 · Open Heart
  31. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores
    Vanessa Roldán, Vicente Vicente, Mariano Valdés, Gregory Y.H. Lip, María Asunción Esteve‐Pastor, José Miguel Rivera‐Caravaca, Francisco R. Marín · 2017 · Thrombosis and Haemostasis
  32. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population‐Based Study
    Amy Yu, Shaun Malo, Lawrence W. Svenson, Stephen B. Wilton, Michael D. Hill · 2017 · Journal of the American Heart Association
  33. Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device
    Saurav Chatterjee, Howard C. Herrmann, Robert L. Wilensky, John Hirshfeld, Daniel McCormick, David S. Frankel, Robert W. Yeh, Ehrin J. Armstrong, Dharam J. Kumbhani, Jay S. Giri · 2015 · JAMA Internal Medicine
  34. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective ‘Real-world’ Inception Cohort Study
    Vanessa Roldán, Shirley Cancio, Josefa Gálvez, Mariano Valdés, Vicente Vicente, Francisco R. Marín, Gregory Y.H. Lip · 2015 · The American Journal of Medicine
  35. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores
    José Miguel Rivera‐Caravaca, Francisco R. Marín, Juan Antonio Vilchez, Josefa Gálvez, María Asunción Esteve‐Pastor, Vicente Vicente, Gregory Y.H. Lip, Vanessa Roldán · 2019 · Stroke
  36. Health-related quality of life, anxiety and depression up to 12 months post-stroke: Influence of sex, age, stroke severity and atrial fibrillation – A longitudinal subanalysis of the Find-AFRANDOMISED trial
    Monika Sadlonova, Katrin Wasser, Jonas Nagel, Mark Weber-Krüger, Sonja Gröschel, Timo Uphaus, Jan Liman, Gerhard F. Hamann, Pawel Kermer, Klaus Gröschel et al. · 2021 · Journal of Psychosomatic Research
  37. Thrombi of Different Pathologies: Implications for Diagnosis and Treatment
    Carlos G. Santos‐Gallego, Jeremías Bayón, Juan J. Badimón · 2010 · Current Treatment Options in Cardiovascular Medicine
  38. Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study
    Gregory Y.H. Lip, Lars Hvilsted Rasmussen, Flemming Skjøth, Kim Overvad, Torben Bjerregaard Larsen · 2012 · BMJ Open
  39. P-wave Dispersion for Predicting Paroxysmal Atrial Fibrillation in Acute Ischemic Stroke
    Umuttan Doğan, Ebru Apaydın Doğan, Mehmet Tekinalp, Osman Serhat Tokgöz, Alpay Arıbaş, Hakan Akıllı, Kurtuluş Özdemir, Hasan Gök, Betigül Yürüten · 2012 · International Journal of Medical Sciences
  40. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study
    Stefan Hans Hohnloser, Edin Basic, Michael Näbauer · 2019 · Thrombosis and Haemostasis
  41. Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices
    Wanyi Chen, Shaan S. Khurshid, Daniel E. Singer, Steven J. Atlas, Jeffrey M. Ashburner, Patrick T. Ellinor, David D. McManus, Steven A. Lubitz, Jagpreet Chhatwal · 2022 · JAMA Health Forum
  42. Left atrial appendage exclusion: State‐of‐the‐art
    Ignacio Cruz‐González, Bryan P. Yan, Yat‐Yin Lam · 2009 · Catheterization and Cardiovascular Interventions
  43. Systematic screening for the detection of atrial fibrillation
    Patrick S. Moran, Conor Teljeur, Máirín Ryan, Susan M. Smith · 2016 · Cochrane Database of Systematic Reviews
  44. Percutaneous Coronary Intervention of Saphenous Vein Graft
    Björn Redfors, Philippe Généreux, Bernhard Witzenbichler, Thomas McAndrew, Jamie Elizabeth Diamond, Xin Huang, Akiko Maehara, Giora Weisz, Roxana Mehran, Ajay Jayant Kirtane et al. · 2017 · Circulation Cardiovascular Interventions
  45. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases
    Laëtitia Huiart, Cyril Ferdynus, Christel Renoux, Amélie Beaugrand, Sophie Lafarge, Léa Bruneau, Samy Suissa, Olivier Maillard, Xavier Ranouil · 2018 · BMJ Open
  46. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: Implications for atrial fibrillation screening.
    H. Gibbs, B. Freedman, M. Rosenqvist, S. Virdone, W. Al Mahmeed, G. Ambrosio, A. Camm, B. Jacobson, C. Jerjes-Sánchez, G. Kayani et al. · 2021 · American Journal of Medicine
  47. Thrombosis and Antithrombotic Therapy in Women
    Alison L. Bailey, Dawn C. Scantlebury, Susan S. Smyth · 2009 · Arteriosclerosis Thrombosis and Vascular Biology
  48. Effectiveness of systematic screening for the detection of atrial fibrillation
    Patrick S. Moran, Martin J Flattery, Conor Teljeur, Máirín Ryan, Susan M. Smith · 2013 · Cochrane Database of Systematic Reviews
  49. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta‐analysis
    Massimo Franchini, Carlo Mengoli, Mario Cruciani, Carlo Bonfanti, Pier Mannuccio Mannucci · 2014 · Journal of Thrombosis and Haemostasis
  50. Atrial Fibrillation Associated with Heart Failure, Stroke and Mortality.
    Stefano Bordignon, Maria Chiara Corti, Claudio Bilato · 2012 · Europe PMC (PubMed Central)
  51. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Ping G. Tepper, Jack Mardekian, Cristina Masseria, Hemant M. Phatak, Shital Kamble, Younos Abdulsattar, William Petkun, Gregory Y.H. Lip · 2018 · PLoS ONE
  52. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
    Alexander Philipp Benz, Stefan Hans Hohnloser, John W. Eikelboom, Anthony Carnicelli, Robert Patrick Giugliano, Christopher Bull Granger, Josephine Harrington, Ziad Hijazi, David A. Morrow, Manesh R. Patel et al. · 2023 · European Heart Journal
  53. Interaction of heart failure and stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis
    W. Doehner, M. Böhm, G. Boriani, C. Christersson, A. Coats, K. Haeusler, I. Jones, G. Lip, M. Metra, G. Ntaios et al. · 2023 · European Journal of Heart Failure
  54. Cryptogenic stroke: Is silent atrial fibrillation the culprit?
    Taya V. Glotzer, Paul Ziegler · 2014 · Heart Rhythm
  55. Mean platelet volume: a potential biomarker of the risk and prognosis of heart disease
    Dong-Hyun Choi, Seong‐Ho Kang, Heesang Song · 2016 · The Korean Journal of Internal Medicine
  56. Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients
    Shunsuke Kubo, Yukiko Mizutani, Krissada Meemook, Yoshifumi Nakajima, Asma Hussaini, Saibal Kar · 2017 · JACC. Clinical electrophysiology
  57. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation
    Sachin J. Shah, Daniel E. Singer, Margaret C. Fang, Kristi Reynolds, Alan S. Go, Mark H. Eckman · 2019 · Circulation Cardiovascular Quality and Outcomes
  58. Atrial Fibrillation
    A. John Camm, Irina Savelieva, Siew Yen Ho, Bruce D. Lindsay, Stanley Nattel, Kaori Shinagawa · 2009 · Elsevier eBooks
  59. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
    Danielle Clarkesmith, Helen M. Pattison, Deirdre A. Lane · 2013 · Cochrane Database of Systematic Reviews
  60. Evaluación del grado de anticoagulación de pacientes con fibrilación auricular en el ámbito de atención primaria de Galicia. Estudio ANFAGAL
    Sergio Cinza‐Sanjurjo, Daniel Rey Aldana, Enrique Gestal-Pereira, Carlos Calvo-Gómez · 2014 · Revista Española de Cardiología
  61. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
    Jonas Bjerring Olesen, Christian Tobias Torp-Pedersen · 2015 · Thrombosis and Haemostasis
  62. Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies
    Jonathan G. Best, Gareth Ambler, Duncan Wilson, Keon‐Joo Lee, Jae‐Sung Lim, Masayuki Shiozawa, Masatoshi Koga, Linxin Li, Caroline E. Lovelock, Hugues Chabriat et al. · 2021 · The Lancet Neurology
  63. Lone atrial fibrillation: what is known and what is to come
    T. Potpara, G. Y. Lip · 2011 · International journal of clinical practice
  64. Paroxysmal Atrial Fibrillation in Cryptogenic Stroke: A Case–Control Study
    Alejandro A. Rabinstein, Jennifer E. Fugate, Jay N. Mandrekar, Joseph D. Burns, Raymond C.S. Seet, Stefan A. Dupont, Timothy J. Kauffman, Samuel J. Asirvatham, Paul A. Friedman · 2013 · Journal of Stroke and Cerebrovascular Diseases
  65. Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation
    Winnie W. Nelson, Jiyoon C. Choi, Julie Vanderpoel, ChandrasekharRao Venkata Damaraju, Peter Wildgoose, Larry E. Fields, Jeffrey R Schein · 2013 · The American Journal of Cardiology
  66. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists
    Vicente Bertoméu, Angel R. Cequier, Francisco R. Marín, Manuel P. Anguita, Martín Ruiz Ortiz · 2015 · Thrombosis and Haemostasis
  67. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor
    Laurent Fauchier, Coralie Lecoq, Nicolas Clémenty, Anne Brunet Bernard, Denis Angoulvant, Fabrice Ivanés, Dominique Babuty, Gregory Y.H. Lip · 2015 · CHEST Journal
  68. Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality
    Karen C. Albright, Lei Huang, Justin L. Blackburn, George Howard, Michael T. Mullen, Vera Bittner, Paul Muntner, Virginia J. Howard · 2018 · Neurology
  69. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study
    Luisa Ibáñez, Mònica Sabaté, Xavier Vidal, Elena Ballarín, Marietta Rottenkolber, Sven Schmiedl, Andreas Heeke, Consuelo Huerta, Elisa Martín‐Merino, Dolores Montero et al. · 2019 · British Journal of Clinical Pharmacology
  70. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation
    Ganesan Karthikeyan, Stuart J. Connolly, Mpiko Ntsekhe, Alexander Philipp Benz, Sumathy Rangarajan, Gayle Lewis, Yan Yun, Sanjib Kumar Sharma, Fathi Maklady, Alaa Elghamrawy et al. · 2020 · American Heart Journal
  71. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial
    Roland C. Veltkamp, Eleni Korompoki, Kirsten Harvey, Emily R. Harvey, Cornelia Fießler, Uwe Malzahn, Viktoria Rücker, Joan Montaner, Valeria Caso, Igor Sibon et al. · 2025 · The Lancet
  72. Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients
    Masato Kaneko, Takahiko Tanigawa, Kensei Hashizume, Mariko Kajikawa, Masahiro Tajiri, Wolfgang Mueck · 2013 · Drug Metabolism and Pharmacokinetics
  73. Hematoma Formation During Breast Core Needle Biopsy in Women Taking Antithrombotic Therapy
    Alison Lynn Chetlen, Claudia J. Kasales, Julie A. Mack, Susann E. Schetter, Junjia Zhu · 2013 · American Journal of Roentgenology
  74. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents
    Thomas Pilgrim, Bindu Kalesan, Thomas Zanchin, Cédric Pulver, Simon C. Jung, Heinrich Paul Mattle, Thierry Pierre Carrel, Aris Moschovitis, Stefan Stortecky, Peter Wenaweser et al. · 2013 · EuroIntervention
  75. Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting
    Pak‐Hei Chan, Chun‐Ka Wong, Louise Pun, Yu‐Fai Wong, Michelle Man‐Ying Wong, Daniel Wai‐Sing Chu, Chung‐Wah Siu · 2017 · BMJ Open
  76. Association Between Use of Antithrombotic Medication and Hematuria-Related Complications
    Christopher J. D. Wallis, Tristan Juvet, Yuna Lee, Rano Matta, Sender Herschorn, Ronald T. Kodama, Girish S. Kulkarni, Raj Satkunasivam, William H Geerts, Anne G. McLeod et al. · 2017 · JAMA
  77. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
    Jan Steffel, Christian Thomas Ruff, Ophelia Q. P. Yin, Eugene Braunwald M. D, Jeong‐Gun Park, Sabina A. Murphy, Stuart J. Connolly, Elliott Marshall Antman, Robert Patrick Giugliano · 2021 · Journal of the American College of Cardiology
  78. Screening for Atrial Fibrillation
    Leila C. Kahwati, Gary N Asher, Zachary O. Kadro, Susan Keen, Rania Ali, Emmanuel Coker‐Schwimmer, Daniel E Jonas · 2022 · JAMA
  79. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review
    B. Anandasundaram, Deirdre A. Lane, Stavros Z. Apostolakis, Gregory Y.H. Lip · 2013 · Journal of Thrombosis and Haemostasis
  80. Relationships between Anticoagulation, Risk Scores and Adverse Outcomes in Dialysis Patients with Atrial Fibrillation
    Tom Kai Ming Wang, Janarthanan Sathananthan, Mark Roger Marshall, Andrew Kerr, Chris Hood · 2015 · Heart Lung and Circulation
  81. Underutilization of Ambulatory ECG Monitoring After Stroke and Transient Ischemic Attack
    Jodi D. Edwards, Moira K. Kapral, Jiming Fang, Gustavo Saposnik, David J. Gladstone · 2016 · Stroke
  82. Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis
    P. Petryszyn, P. Niewiński, A. Staniak, P. Piotrowski, Anna R. Well, M. Well, Izabela Jęśkowiak, G. Lip, P. Ponikowski · 2019 · PLoS ONE
  83. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy
    Michael G. Fradley, Matthew Gliksman, Josephine Emole, Federico Viganego, Isaac B. Rhea, Allan Welter-Frost, Merna A. Armanious, Dae Hyun Lee, Christine Marie Walko, Bijal Dinesh Shah et al. · 2019 · The American Journal of Cardiology
  84. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation
    Ron Pisters, Robby Nieuwlaat, Deirdre A. Lane, Harry J.G.M. Crijns, Gregory Y.H. Lip · 2012 · Thrombosis and Haemostasis
  85. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists
    Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Sergio Raposeiras‐Roubín, Andrea López-López, Alfredo Redondo Diéguez, Diego Álvarez-Iglesias, Moisés Rodríguez‐Mañero, Carlos Peña, José Ramón González‐Juanatey · 2015 · EP Europace
  86. Should oral anticoagulant therapy be continued during dental extraction? A meta-analysis
    Shuo Yang, Quan Shi, Jinglong Liu, Jinru Li, Juan Xu · 2016 · BMC Oral Health
  87. 2026 ESC Guidelines for the management of heart failure
    Lars Køber, Marianna Adamo, Anne‐Christine Ruwald, Daniela Tomasoni, Lisa Anderson, Charlotte Andersson, Jasper Jan Brugts, Ovidiu Dragomir Chioncel, Erwan Donal, Péter Ferdinandy et al. · 2026 · European Heart Journal
  88. Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study
    Brigitta U. Monz, Stuart J. Connolly, M. Korhonen, Herbert Noack, Jayne Pooley · 2013 · International Journal of Cardiology
  89. Reasons Underlying Non-Adherence to and Discontinuation of Anticoagulation in Secondary Stroke Prevention among Patients with Atrial Fibrillation
    Christoph Gumbinger, Timo Holstein, Christian Stock, Timolaos Rizos, Solveig Horstmann, Roland C. Veltkamp · 2015 · European Neurology
  90. Net Clinical Benefit of Warfarin Therapy in Elderly Chinese Patients With Atrial Fibrillation
    Chung‐Wah Siu, Hung‐Fat Tse · 2014 · Circulation Arrhythmia and Electrophysiology
  91. Diabetes and Stroke Prevention: A Review
    Jonathan Hewitt, Luis Castilla Guerra, María del Carmen Fernández‐Moreno, Cristina Sierra · 2012 · Stroke Research and Treatment
  92. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study)
    Toni Grönberg, Juha E.K. Hartikainen, Ilpo O. Nuotio, Fausto Biancari, Antti Ylitalo, Juhani K.E. Airaksinen · 2016 · The American Journal of Cardiology
  93. CYP2C9 Genotype‐Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R‐ and S‐Warfarin and Their Oxidative Metabolites
    Darcy R. Flora, Allan E. Rettie, Richard C. Brundage, Timothy S. Tracy · 2016 · The Journal of Clinical Pharmacology
  94. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry
    Menno Volkert Huisman, Kenneth Jay Rothman, Miney Paquette, Christine Teutsch, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Chang Sheng, Kristina Zint, Amelie Elsaesser et al. · 2017 · American Heart Journal
  95. Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
    Gregory Y.H. Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant M. Phatak · 2018 · PLoS ONE
  96. Cardiovascular Therapies Targeting Left Atrial Appendage
    Mohit K. Turagam, Poonam Velagapudi, Saibal Kar, David R. Holmes, Vivek Yerrapu Reddy, Marwan M. Refaat, Luigi Di Biase, Amin Al‐Ahmed, Mina K. Chung, Thorsten Lewalter et al. · 2018 · Journal of the American College of Cardiology
  97. eHealth Tools to Provide Structured Assistance for Atrial Fibrillation Screening, Management, and Guideline‐Recommended Therapy in Metropolitan General Practice: The AF‐SMART Study
    Jessica Joan Orchard, Lis Neubeck, Ben Freedman, Jialin Li, Ruth J Webster, Nicholas Arnold Zwar, Robyn D Gallagher, Caleb Ferguson, Nicole Lowres · 2018 · Journal of the American Heart Association
  98. Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice: a cluster randomised controlled trial
    Femke Kaasenbrood, Monika Hollander, Steven HM de Bruijn, Carlijn PE Dolmans, Robert G. Tieleman, Arno Wilhelmus Hoes, Frans Hendrik Rutten · 2020 · British Journal of General Practice
  99. Nationwide Trends in Incidence and Mortality of Stroke Among Younger and Older Adults in Denmark
    Nils Skajaa, Kasper Adelborg, Erzsébet Horváth–Puhó, Kenneth Jay Rothman, Victor W. Henderson, Lau Caspar Thygesen, Henrik Toft Sørensen · 2021 · Neurology
  100. Left Atrial Appendage Ligation in Nonvalvular Atrial Fibrillation Patients at High Risk for Embolic Events With Ineligibility for Oral Anticoagulation
    Horst Sievert, Abdi Rasekh, Kryzstof Bartus, Remo Morelli, Qizhi Fang, Jonas Kuropka, Duong L. Le, Sameer A. Gafoor, Luisa Heuer, Payam Safavi‐Naeini et al. · 2015 · JACC. Clinical electrophysiology